The Lung Infection Nobody Talks About Just Got a Real Treatment

The ENCORE trial was specifically designed to unlock that dinner crowd. By proving ARIKAYCE works in patients who haven't yet started antibiotics (the "antibiotic-naive" group), Insmed can now petition the FDA to expand the drug's label to first-line use. The company plans to submit a supplemental application in the second half of 2026, with a similar filing in Japan.

If approved, this would transform ARIKAYCE from a last-resort option into a frontline weapon. For a drug already generating over $107 million in a single quarter (Q2 2025, up 19% year-over-year), the commercial implications are enormous. Analysts project global ARIKAYCE revenues north of $450 million in 2026.

A Company That Reinvented Itself

Insmed's backstory reads like a biotech coming-of-age movie. Founded in 1988, the company originally focused on diabetes. It went public in 2000 through a reverse merger, spent years searching for its identity, and then made a pivotal acquisition in 2010: a small company called Transave that had been developing inhaled liposomal antibiotics.

That one deal changed everything. The Transave technology became ARIKAYCE, which earned accelerated FDA approval in September 2018, followed by European approval in October 2020 and Japanese approval in March 2021. Along the way, Insmed also picked up brensocatib (now branded Brinsupri), an oral treatment for bronchiectasis that pulled in $172.7 million in 2025 revenue with guidance of at least $1 billion for 2026.

The ENCORE data dropped at a complicated moment for the company. Brensocatib recently failed a trial in rhinosinusitis (chronic sinus inflammation), which stung. But the ARIKAYCE win more than offset that bruise; Insmed's stock jumped over 5% on the news.

The Bigger Picture for Rare Lung Diseases

MAC lung disease sits in one of those frustrating corners of medicine where prevalence is rising but awareness stays stubbornly low. Cases are climbing across every major market, driven by aging populations and better diagnostic tools catching infections that previously flew under the radar. Most NTM (nontuberculous mycobacterial) strains are naturally resistant to standard tuberculosis drugs, which means patients need specialized, sometimes grueling treatment regimens.

The FDA has been increasingly receptive to rare disease therapies. In 2025, 50% of the agency's novel drug approvals (23 out of 46) were designated as rare disease treatments. That regulatory tailwind, combined with a growing pipeline of experimental MAC therapies from other companies, suggests this corner of pulmonology is finally getting the attention it deserves.

For Insmed, the path forward is clear: file the supplemental application, get the broader label, and capture a patient population that has been waiting for better options. The earlier ARISE study showed that ARIKAYCE patients achieved significantly higher culture conversion rates compared to standard therapy alone, giving the regulatory submission a strong foundation.

What to Watch Next

Insmed plans to present the full ENCORE dataset at a medical conference (timing not yet announced). The supplemental FDA filing is targeted for the back half of 2026, with analysts penciling in a potential 2027 launch for the expanded indication.

The real question isn't whether the data is good enough. It clearly is. The question is whether a broader label can turn ARIKAYCE into a billion-dollar product on its own, joining brensocatib in what would be a genuinely rare achievement: a mid-cap biotech with two blockbuster respiratory drugs.

For the approximately 119,000 patients across major markets living with MAC lung disease, the corporate math matters less than the clinical reality. A drug that was once reserved for treatment failures could soon be the first thing their doctor reaches for. That's not just a label change. That's a fundamentally different standard of care.

The Drug That Finally Cracked the Brain's Toughest Bouncer

For nearly 20 years, kids with Hunter syndrome had a treatment that couldn't reach their brains. Denali Therapeutics just got FDA approval for Avlayah, the first enzyme therapy that crosses the blood-brain barrier, and it could change the game for rare neurological diseases.